This article reviews policies and ethical practices, revealing implications for biotechnology governance in China.
Ethics is a core issue that life sciences cannot avoid. In the past two decades, China has entered a high-speed development mode in the field of biotechnology, achieving many significant results, but also exposing a series of ethical issues. Among them, the most questioned is undoubtedly the He Jiankui gene editing incident. In fact, China has been promoting the establishment and improvement of technology ethics review, and the He Jiankui incident has rapidly accelerated this process. This article reviews the policies and regulations of the past and recent years to illustrate the establishment and improvement process of China’s scientific and technological ethics review.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: